ONCO/Reveal™
Solid Tumor Genetic Test

What is Solid Tumor Genetic Test?

It detects numerous, relevant gene regions of interest for researchers looking to explore the genetic sequences of both germline and formalin-fixed paraffin-embedded (FFPE) DNA samples from solid tumor samples. The panel utilizes Pillar Biosciences’ proprietary SLIMamp® (stem-loop inhibition mediated amplification) technology, allowing researchers to amplify regions of interest in a simple, multiplex reaction for subsequent sequencing on a sequencer using a paired-end read length of 150 (2×150).

In 2020, Asia reported the most outrageous number of new cancer cases and death worldwide. According to global data conducted by World Health Organization, approximately 9 million of new cases were diagnosed respectively among Asian, together with 5 million deaths.

Reduction of mortality from a specific cancer can be achieved by early cancer screening and diagnosis. With the next generation sequencing (NGS) technique, it holds the promise of detecting tumour mutations on either tumour cells or free circulating tumour DNA in a comprehensive and concise way for physicians to select appropriate targeted therapeutical drugs for cancer treatment. An early diagnosis opens the door to future care and cancer treatment, increasing the overall survival rate.

目標

Researchers looking to explore the genetic sequences of both germline and formalin-fixed paraffin-embedded (FFPE) DNA from solid tumour samples.

Table 1: Gene List

AKT1	DDR2	FGFR2	HRAS	NRAS	PTEN	SRSF2
ALK	EGFR	FGFR3	IDH1	NTRK1	PTPN11	STK11
ARAF	EIF1AX	GNA11	IDH2	PDGFRA	RAC1	TERT
BRAF	ERBB2	GNAQ	KIT	PIK3CA	RAF1	TP53
CDKN2A	ERBB4	GNAS	KRAS	PLCB4	RET	TSHR
CTNNB1	FBXW7	H3F3A	MAP2K1	POLD1	SF3B1
CYSLTR2	FGFR1	HIST1H3B	MET	POLE	SMAD4

Table 1: Gene List

AKT1	DDR2	FGFR2	HRAS	NRAS
PTEN	SRSF2	ALK	EGFR	FGFR3
IDH1	NTRK1	PTPN11	STK11	ARAF
PIK3CA	RAF1	TP53	CDKN2A	ERBB4
CTNNB1	FBXW7	H3F3A	MAP2K1	POLD1
SF3B1	CYSLTR2	FGFR1	HIST1H3B	MET
POLE	SMAD4

AKT1	Solid Tumor Genetic Test
Content	47 genes detected from solid tumour (please refer to table 1 for details)
Sequencing Platform	NGS
Sequencing Type	Amplicon based sequencing
Variants Type	SNVs, indel and medium indels
Sample Type	FFPE
TAT	7 working days**